Evidence map›Paper›PMID 41773582›Full record

ArticleHuman vaccines & immunotherapeutics2026

Trends in clinical intervention practice for preventing mother-to-child transmission of hepatitis B virus in Guangdong Province, 2021-2023.

Shuang Gao, Tiancheng Xie, Min Cai, Mengyang Su, Tianshuo Zhao, Xiyu Zhang, Sihui Zhang, Mingting Wang, Qingsong Xu, Yujie Cheng and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shuang GaoDepartment of Maternity Group Health, Guangdong Women and Children Hospital, Guangzhou, P. R. China.
Tiancheng XieDepartment of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, P. R. China.
Min CaiDepartment of Maternity Group Health, Guangdong Women and Children Hospital, Guangzhou, P. R. China.
Mengyang SuDepartment of Maternity Group Health, Guangdong Women and Children Hospital, Guangzhou, P. R. China.
Tianshuo ZhaoDepartment of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, P. R. China.
Xiyu ZhangDepartment of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, P. R. China.
Sihui ZhangDepartment of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, P. R. China.
Mingting WangDepartment of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, P. R. China.
Qingsong XuDepartment of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, P. R. China.
Yujie ChengDepartment of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, P. R. China.
Fuqiang CuiDepartment of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, P. R. China.
Fenghua LiuDepartment of Maternity Group Health, Guangdong Women and Children Hospital, Guangzhou, P. R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Guangdong Province in China is endemic for hepatitis B virus (HBV) infection with a high prevalence of chronic HBV infection in pregnant women. Measures have been taken to reduce mother-to-child transmission (MTCT) of HBV. This study aims to analyze the trends in these preventive measures in hepatitis B surface antigen (HBsAg)-positive pregnant women from 2021 to 2023. Data were obtained from the case report forms of HBsAg-positive pregnant women and their newborns that were completed and reported in Guangdong Province through the Information System of the National Integrated Prevention of Mother-to-Child Transmission of HIV, syphilis and hepatitis B Programme from January 1, 2021, to December 31, 2023. The Cochran-Armitage test was employed to analyze trends in maternal hepatitis B e antigen (HBeAg) positivity rates across different age groups of pregnant women, antiviral treatment rates in the total and HBeAg-positive populations, and the coverage of timely birth dose of the hepatitis B vaccine (HepB-BD) and hepatitis B immunoglobulin (HBIG) among infants born to the total and HBeAg-positive pregnant women from 2021 to 2023. A total of 283,959 HBsAg-positive pregnant women and their newborns were included in the study. The HBeAg positivity rate among the HBsAg-positive pregnant women was 26.1%. The prevalence of HBeAg positivity among HBsAg-positive pregnant women in Guangdong Province experienced a declining trend from 2021 to 2023. Over the same period, the uptake of antiviral treatment increased in both the overall population and the HBeAg-positive subgroup, with the proportion of HBeAg-positive pregnant women receiving antiviral therapy rising from 23.8% in 2021 to 51.8% in 2023. The proportion of HBV-exposed newborns receiving both HepB-BD and HBIG within 12 hours of birth also increased steadily, with coverage exceeding 97% in 2023. This study highlights significant progress in reducing MTCT of hepatitis B in Guangdong Province from 2021 to 2023. HBeAg positivity among HBsAg-positive pregnant women declined, while both the uptake of antiviral therapy and the timely administration of HepB-BD and HBIG to HBV-exposed infants improved markedly. These findings underscore the important role of public health interventions while emphasizing the need for sustained efforts, particularly for young HBeAg-positive pregnant women.

Indexed as

Hepatitis BHepatitis B, ChronicInfectious Disease Transmission, VerticalPregnancy Complications, InfectiousAdolescentAdultAntiviral AgentsChinaFemaleHepatitis B e AntigensHepatitis B Surface AntigensHepatitis B VaccinesHepatitis B virusHumansImmunoglobulinsInfant, NewbornAntiviral AgentsHepatitis B e Antigenshepatitis B hyperimmune globulinHepatitis B Surface AntigensHepatitis B VaccinesImmunoglobulinsantiviral therapyHepatitis B virusmother-to-child transmissionpregnant womenreal-world study

Identifiers

PMID41773582
PMCPMC12959201

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.